News

2024

 January 6, 2024

Hansa Biopharma and NewBridge Pharmaceuticals

Hansa Biopharma and NewBridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix® to Kidney Transplant Patients in the Middle East and North Africa

Read More
 January 4, 2024

كيف تعيد نيوبريدج تحديد معايير قطاع الصناعات الدوائية

فورتشن 500 العربية - كيف تعيد نيوبريدج تحديد معايير قطاع الصناعات الدوائية في المنطقة

Read More
 January 4, 2024

NewBridge Defining the Norms

NewBridge Defining the Norms: An Exclusive Interview with Joe Henein, President & CEO of NewBridge Pharmaceuticals in MENA

Read More

2023

 September 20, 2023

Joe Henein, President & CEO of NewBridge Pharmaceuticals, on CNBC

Watch Joe Henein, President & CEO of NewBridge Pharmaceuticals, on CNBC Arabia's "Masterminds" documentary talking about NewBridge Pharmaceuticals’ journey and Healthcare in the Middle East.

Read More
 August 24, 2023

Joe Henein – President & CEO, Newbridge Pharmaceuticals

NewBridge Pharmaceuticals’ Joe Henein describes how his MENA-focused specialty innovative biopharma distributor has developed over the last 13 years to become a market leader.

Read More
 June 22, 2023

NEWBRIDGE ANNOUNCES AGREEMENT FOR DISTRIBUTION OF BIOGEN MULTIPLE SCLEROSIS THERAPIES IN THE MIDDLE EAST AND NORTH AFRICA

Dubai, United Arab Emirates, [21 June 2023] NewBridge Pharmaceuticals (“NewBridge” or “the Company”) announce that they have entered a distribution agreement with Biogen International GmbH (Biogen).

Read More
 May 2, 2023

In Saudi Arabia, A Vision Of Healthcare Spurs Growth

Newbridge has been collaborating with the scientific community to help them adopt advanced technologies such as genomic and biomarker testing as well as liquid biopsy in an effort to increase diagnosis and personalize therapy.

Read More

2022

 August 18, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO® (berotralstat)

Read More
 June 13, 2022

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

BeiGene and NewBridge Pharmaceuticals To Bring BRUKINSA to Patients in MENA Region, Following Approval for Previously Treated Mantle Cell Lymphoma in Kuwait, Bahrain and Qatar

Read More
 June 8, 2022

NewBridge Pharmaceuticals expanded its operations with Dubai Science Park (DSP)

NewBridge Pharmaceuticals expanded its operations with Dubai Science Park (DSP), the leading science-focused community part of TECOM Group, to better address the unmet medical needs of patients across the region.

Read More
 May 23, 2022

NewBridge Pharmaceutical expands operations in Dubai Science Park to enhance access to markets across the MENA region

Pharmaceutical specialty company NewBridge Pharmaceuticals has announced that it will be expanding its operations with Dubai Science Park (DSP), the leading science-focused community part of TECOM Group,

Read More
 February 1, 2022

Joe Henein, NewBridge Pharmaceuticals President & CEO, in Al Bayan Economic Magazine: Issue 603, February 2022

شركة NEWBRIDGE PHARMACEUTICALS جو حنين: رئيس مجلس الإدارة والمدير التنفيذي مستمرون في بذل جهود مضاعفة لتأمين وتقديم الأدوية المتخصصة والمبتكرة لشركائنا وعملائنا في المنطقة رغم التحديات

Read More

2021

 November 18, 2021

BioCryst Announces Approval Of ORLADEYO® (Berotralstat) In United Arab Emirates

Company selects NewBridge Pharmaceuticals as regional distributor in Gulf Cooperation Council RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE)…

Read More
 November 14, 2021

BeiGene And NewBridge Pharmaceuticals Announce Approval In Saudi Arabia Of BRUKINSA® (Zanubrutinib) For The Treatment Of Patients With Relapsed Or Refractory Mantle Cell Lymphoma

BeiGene and NewBridge Pharmaceuticals are working together to rapidly advance BRUKINSA in the Middle East and North African (MENA) region…

Read More
 July 20, 2021

Pharming Signs Agreement With NewBridge Pharmaceuticals For The Commercialization Of Ruconest® In The Middle East And North Africa

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces it has entered into an exclusive licence agreement…

Read More

2019

 May 1, 2019

NewBridge Pharmaceuticals -2018 Winner Of The Most Innovative Pharmaceutics

"The www.CFI.co judging panel applauds the company’s mission to address unmet medical needs in the MENA region through strategic joint-ventures…

Read More
 May 1, 2019

NewBridge Pharmaceuticals -2018 Winner Of The Most Innovative Pharmaceutics

"The www.CFI.co judging panel applauds the company’s mission to address unmet medical needs in the MENA region through strategic joint-ventures…

Read More

2018

 December 13, 2018

Multiple Products, Multiple Geographies

TBY talks to Joe Henein, CEO of NewBridge Pharmaceuticals, on building brands, supporting SMEs in the region, and driving innovation.…

Read More
 May 16, 2018

12th International Pharmaceutical And Medical Device Compliance Congress

Joe Henein, President & CEO, NewBridge Pharmaceuticals is attending the 12th International Pharmaceutical and Medical Device C...

Read More

2017

 December 12, 2017

Reaching New Heights

TBY talks to Joe W. Henein, CEO & President of NewBridge Pharmaceuticals, on the importance of increased access to medicin...

Read More

2016

 November 30, 2016

Ever Wider Access

TBY talks to Joe W. Henein, President & CEO of NewBridge Pharmaceuticals, on the attractivenss of the MENA region to pharmaceu...

Read More
 November 30, 2016

Sunovion Pharmaceuticals Europe Ltd. and NewBridge Pharmaceuticals Announce Agreement for Distribution of Latuda® (lurasidone) in the Gulf Cooperation Council Region

Sunovion Pharmaceuticals Europe Ltd. and NewBridge Pharmaceuticals Announce Agreement for Distribution of Latuda® (lurasidone) in the Gulf Cooperation Council Region

Read More
 August 30, 2016

Aramex Inks Deal With NewBridge Pharmaceuticals

Published: 18:40 August 23, 2016 (Gulf News) Dubai: Aramex on Tuesday announced its partnership with NewBridge Pharmaceutica...

Read More
 June 15, 2016

MoH Signs MoU With NewBridge To Provide Free Treatment For Patients With

DUBAI, 15th June, 2016 (WAM) – The Ministry of Health and Prevention has signed a Memorandum of Understanding (MoU) with NewBrid...

Read More
 June 15, 2016

300 UAE Arthritis Patients To Receive Free Treatment

According to Dr Amiri, all patients will be assessed medically and financially before being provided this treatment Three...

Read More

2015

 March 31, 2015

NewBridge Continues To Bridge Innovation From West To East

Joe W. Henein, President and CEO of NewBridge Pharmaceuticals, says bringing specialty medicines to the region will remain their k...

Read More